Jennifer Woyach
Director of the Division of Hematology · Ohio State University Hospital
Credentials: · · · ·
History
PresentLeukemia and Hematologic Malignancies Program · Ohio State University Hospital
- 2008–2011
Hematology and Medical Oncology
Research
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
New England Journal of Medicine · 2014 · First of 25 authors · 1,075 citations
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
New England Journal of Medicine · 2018 · First of 31 authors · 782 citations
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2016 · 761 citations
- JB
132 papers
- KR
66 papers
45 papers
39 papers
33 papers
31 papers · 2 as a fellow
- JJ
29 papers
- MG
29 papers
Grants
- 2019–2032
OSU as a Network Lead Academic Participating Site for the NCI NCTN
National Cancer Institute · UG1
PI · $1.1M · Ohio State University
- 2026–2031
Rationally Directed Therapy for CLL
National Cancer Institute · R01
PI · $690K · University of Tx Md Anderson Can Ctr
- 1997–2031
National Cancer Institute · P30
Project lead · $161.6K · Ohio State University
- 2013–2026
Targeted Therapies for Lymphoid Malignancies
National Cancer Institute · R01
Contact PI · $3.2M · Ohio State University
Clinical trials
- 2026–2027
Principal investigator · Not yet recruiting · Phase 2
Jennifer Woyach
- 2026–2027
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Principal investigator · Recruiting · Phase 2
Jennifer Woyach
- 2023–2026
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Principal investigator · Recruiting · Phase 2
Aseel Alsouqi
- 2020–2022
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Principal investigator · Completed · Phase 1
Jennifer Woyach